LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

NCT01726738 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Stage III Melanoma
Stage IV Melanoma
Unresectable Melanoma
BRAF Mutant Melanoma

Interventions

DRUG: BRAF inhibitor dabrafenib and MEK inhibitor trametinib

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

[object Object]